A seed fund based in California focuses on applied AI technologies and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A VC firm based in CA invests in companies in Consumer, Enterprise, as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series seed/A/B rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, Digital Health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunities and disruptive technology. When investing, the firm is willing to lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in 1982, the private equity firm is based in Boston, MA. The firm has raised 8 funds to date totaling approximately $1 billion in total assets raised. The firm is looking to invest $2-15 million preferred equity in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers companies located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. In 2014, The firm launched its Founders Fund through which the firm makes angel investments into high potential, early-stage companies. The Founders Fund typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Healthcare IT, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to the Founders Fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is looking for companies that have at least $2-$30 million in yearly revenue. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Founded in 2011, the firm has worked with more than 35 leading healthcare organizations to advance an innovation strategy that supports a culture of idea generation, business creation, and entrepreneurial collaboration in order to drive sustainable impact. In the past, the firm has managed the Intermountain Healthcare Innovation Fund, a $35 million fund closed in 2015 backed by Intermountain Healthcare, with a focus on health technologies with a provider angle. The firm currently manages the DaVita Venture Fund in partnership with DaVita Venture Group, focusing on early-to-mid stage companies that work on transforming healthcare and improving clinical outcomes. Typical size of an initial investment is $1-3 million in Seed to Series B round. The firm can invest up to $5 million over the lifetime of a company. The firm is open to leading or syndicating in a financing round. The firm is currently seeking opportunities globally, but currently has a focus in the U.S.

The firm considers innovations that have a strategic angle to healthcare providers and do not need to go through regulatory development hurdle. Examples may include healthcare operational improvement,

healthcare workflow management, data analytics, radiologic information analysis, telemedicine, population management, and automated screening.

Supporting the interests of the DaVita Venture Fund, the firm is interested in technologies that improve outcomes and quality of care for patients with kidney disease and other chronic diseases. Within the broad life science sectors, the firm will consider pharmaceuticals and medical devices that can help improve clinical outcomes and reduce costs for the healthcare system, with a preference for those with an accelerated regulatory approval pathway. The firm also considers digital health solutions – tech-enabled products and services that leverage technology, data, and connectivity to improve care delivery.

The firm is looking for competent management teams developing innovative solutions to real-world problems in the healthcare industry. The firm’s limited partner, DaVita Venture Group, is actively involved in the vetting process. The firm also prefers companies whose values align with DaVita Venture Group.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A foundation that was established in 1998 and is based in New York, NY. The foundation is currently funding new investment opportunities in the life science space (specifically Alzheimer’s disease and related dementia) through two grants; the Biotechnology Development Program for existing early stage private companies and the Biotechnology Founders Technology Transfer Program supports the establishment of new companies. The foundation typically provides funding of up to $350,000 per year for up to two years for pre-clinical programs or $1-3 M for clinical stage programs. They will invest with other groups for larger deals. The foundation typically provides investments as equity, a convertible loan, and recoverable grants. The foundation will consider investments globally.

The foundation is currently most interested in companies in the therapeutics space but will consider diagnostics if the technology provides significant benefit for Alzheimer’s patients or will accelerate clinical trials. The foundation is interested in both small molecules and biologics and will providing funding from companies anywhere from High throughput screening to Phase IIa of clinical Trials.

The foundation is looking for companies with experienced management teams. The firm looks to be an active value-added investor to help companies with securing future financing rounds when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm founded in 2002 is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where The firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of an Europe-headquartered bank invests in early-stage companies in the life science industry among other technologically oriented industries, and is looking to engage in late seed, Series A or Series B rounds. The initial investments typically range from 0.5M to 3M Euros. The firm is open to both leading and co-investing, and prefer to syndicate with other investors. The firm is primarily interested in companies based in Germany, Austria and Switzerland.

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices and digital health. The firm is interested in companies from pre-clinical to clinical stages onward, and would like to see some preclinical validations for therapeutics companies or prototypes for medical devices. The firm is opportunistic in terms of sector, subsectors and indications, and is open to considering orphan diseases.

The firm doesn’t have specific requirements for management teams. The firm is open to both leading and co-investing, and prefers to take a board seat when investing larger amounts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.